Skip to content
Menu

BioHarvest Sciences Revises FY26 CDMO Revenue Guidance to $4M-$5M from $4M-$6M; VINIA D2C Revenue Guidance to $33M-$35M from $38M-$42M

Benzinga Newsdesk 3 months ago

NewsGuidance

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA

BioHarvest Sciences (NASDAQ:BHST) stated that full-year 2026 revenue guidance for its CDMO business has been narrowed to $4 million-$5 million, from $4 million-$6 million previously, while revenue guidance for the VINIA D2C business has been revised to $33 million-$35 million, from $38 million-$42 million previously.

 

 

Read at benzinga.com